<DOC>
	<DOCNO>NCT00365599</DOCNO>
	<brief_summary>Phase II trial explore efficacy vorinostat tamoxifen combine .</brief_summary>
	<brief_title>Phase II Trial SAHA &amp; Tamoxifen Patients With Breast Cancer</brief_title>
	<detailed_description>Phase II trial explore efficacy vorinostat tamoxifen combine . Tamoxifen give daily , continuously . Vorinostat give daily 3 4 week ( cycle ) . Responses assess ( restaged ) 2 cycle toxicity capture continuously . Eligible patient receive treatment consecutive 4-week cycle , progression disease unacceptable toxicity . Patients follow evaluation safety least 30 day last dose study drug . Tests obtain pre-and post vorinostat treatment correlate plasma level vorinostat time tumor biopsy vorinostat dose ; test consist : - Patient history - Physical exam ( include height weight ) - Toxicity assessment - Pharmacokinetic ( PK ) sample - Tumor fine needle aspirate ( FNA ) - Peripheral Blood Mononuclear Cells ( PBMC ) - Standard lab Chemistry Profile - Carcinoembryonic antigen ( CEA ) , cancer antigen ( Ca ) 15-3 , Ca 125 ( If clinically indicate ) - Pregnancy Test - Computed tomography ( CT ) scan , magnetic resonance imaging ( MRI ) Documentation response progression evaluate study use Response Evaluation Criteria Solid Tumors ( RECIST ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patients must cytologically/histologically document locally advanced metastatic breast cancer either : 1 . Progression treatment aromatase inhibitor metastatic disease ; 2 . Recurrence adjuvant aromatase inhibitor within 12 month completion ; 3 . Recurrence complete adjuvant tamoxifen least 12 month ; 4 . Patient candidate intolerant aromatase inhibitor treatment ; 5 . Patients allow ( require ) one prior chemotherapy regimen metastatic disease . Tumors must express estrogen progesterone receptor . Patients eligible regardless menopausal status . Age &gt; 18 year old Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients must able give informed consent able follow guideline give study . Patients must acceptable organ function , define follow laboratory parameter : white blood count ( WBC ) &gt; 3.0 x 10^9/L ; absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L ; hemoglobin ( Hgb ) &gt; 10.0g/dL ; platelet ( PLT ) &gt; 100 x 10^9/L , Bilirubin &lt; 2.0 mg/dl , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &lt; 2.5 X upper limit normal ( ULN ) , Creatinine &lt; 1.8 mg/dl ( Creatinine clearance &gt; 60 ml/min ) . Women childbearing age must negative pregnancy test . All patient reproductive potential must use effective method contraception study 6 month follow termination treatment . ( Not applicable patient bilateral oophorectomy and/or hysterectomy female patient older 50 year menstrual cycle one year . Patients must measurable disease RECIST criterion stag study perform within 30 day enrollment . For patient bone disease : For protocol isolate bone lesion classify target lesion measurable MRI screening must follow MRI . Both men woman race ethnic group eligible trial . Patients must receive tamoxifen metastatic disease . Patients must evidence significant active infection ( e.g. , pneumonia , cellulitis , wound abscess , etc . ) time study entry . Patients must diseasefree prior invasive malignancy &gt; 5 year exception : curativelytreated basal cell squamous cell carcinoma skin , carcinoma situ cervix . Pregnant breastfeed woman exclude study effect fetus unknown may risk increase fetal wastage . Patients uncontrolled central nervous system ( CNS ) metastasis history seizure exclude . Patients stable CNS metastasis ( either surgically resect , treat gamma knife stable 3 month follow whole brain radiation therapy [ WBRT ] eligible ) . Patients stable brain metastasis need MRI within 4 week prior start therapy . Patients may receive investigational agent must stop histone deacetylase inhibitor ( include Valproic acid ) hormonal therapy . Patients must discontinue prior therapy breast cancer radiation therapy minimum 3 week , patient exclude radiation therapy give single measurable lesion disease otherwise measurable . Patients exclude know hypersensitivity reaction tamoxifen . Patient history blood clot eligible . Women abnormal vaginal bleeding and/or endometrial hyperplasia cancer eligible . Patients evidence visceral crisis eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Suberoylanilide hydroxamic acid ( SAHA )</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Anti-hormonal therapy</keyword>
	<keyword>Estrogen receptor positive</keyword>
	<keyword>Progesterone receptor positive</keyword>
	<keyword>Metastatic disease</keyword>
	<keyword>Aromatase inhibitor ( Ais )</keyword>
	<keyword>Histone deacetylase ( HDAC ) inhibitor</keyword>
	<keyword>Selective estrogen receptor modulators ( SERMS )</keyword>
</DOC>